Clik here to view.
Prostate cancer technology: Is less more?
Dr. Gomella, a member of the Urology Times Editorial Council, is chair of the department of urology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia. The impact of technology...
View ArticleClik here to view.
Advances in TURP: Focus on the science
Dr. Kaplan, a member of the Urology Times Editorial Council, is professor of urology at Weill Cornell Medical College, New York. Most urologists agree that surgical removal of the enlarged portion of...
View ArticleClik here to view.
Research may yield tailored BPS therapies
Dr. Hanno, a Urology Times editorial consultant, is professor of urology at the University of Pennsylvania, Philadelphia. In this issue of Urology Times, two articles highlight the search for...
View ArticleUrology payment, work force trends are troubling
Of top concern to urologists are declining reimbursement (88%), increasing government regulations (86%), Obamacare (73%), and increasing overhead (71%). This finding—from the most recent Urology Times...
View ArticleClik here to view.
RCC sequencing: One good answer
Leonard G. Gomella, MDDr. Gomella, a member of the Urology Times Editorial Council, is chair of the department of urology, Jefferson Kimmel Cancer Center, Thomas Jefferson University, Philadelphia....
View ArticleClik here to view.
Libido and estradiol: Is there a link?
Lawrence Ross, MDDr. Ross is professor of urology at the University of Illinois, Chicago. Hypogonadism is an increasingly common finding in aging men, those treated for prostate cancer or other...
View ArticleClik here to view.
Robotic radical nephrectomy: Really?
J. Stuart Wolf, Jr., MDDr. Wolf, a member of the Urology Times Editorial Council, is professor of urology at the University of Michigan, Ann Arbor. Two recent studies highlight the increasing use of...
View ArticleClik here to view.
‘Men’s health’ more than a marketing ploy
Dick KerrKerr is group content director of Urology Times. A new emphasis on comprehensive, holistic care of men has emerged in the United States and elsewhere. As our cover article in this issue...
View ArticleClik here to view.
Docs’ frustration may hinder access to care
William F. Gee, MDThe 2014 Urology Times“State of the Specialty” survey shows that urologists remain frustrated with over-regulation by government, control of fees, meaningful use (meaningless use?),...
View ArticleClik here to view.
PSA controversy has practical implications
Dr. AlbertsenScreening for prostate cancer with the PSA test remains extraordinarily controversial. In 2012, the U.S. Preventive Services Task Force recommended against any PSA testing because the...
View ArticleClik here to view.
New hope for treating deep renal tumors?
J. Stuart Wolf, Jr., MDDr. Wolf, a member of the Urology Times Editorial Council, is professor of urology at the University of Michigan, Ann Arbor. A recent Urology Times article highlights interesting...
View ArticleClik here to view.
IC/BPS: Agent brings glimmer of hope
Philip M. Hanno, MD, MPH Dr. Hanno, a Urology Times editorial consultant, is professor of urology at the University of Pennsylvania, Philadelphia. The April 1, 2015 issue of Urology Timesreports on an...
View ArticleClik here to view.
New PCa technologies bring hope, caution
J. Brantley Thrasher, MD Dr. Thrasher, a Urology Times Editorial Consultant, is professor and chair of urology at the University of Kansas, Kansas City. The May 2015 issue of Urology Times discusses...
View ArticleClik here to view.
Dr. Google creates anxiety, opportunity
Steven A. Kaplan, MDDr. Kaplan is E. Darracott Vaughan Jr. Professor of Urology at Weill Cornell Medical College and director of the Iris Cantor Men's Health Center, New York Presbyterian Hospital, New...
View ArticleClik here to view.
PSA screening decline is troubling trend
Henry M. Rosevear, MDDr. Rosevear, a member of the Urology Times Clinical Practice Board, is in private practice in Colorado Springs, CO. I have been practicing urology for just under 2 years now and...
View ArticleClik here to view.
Upfront chemo for PCa? Yes, but…
In 2004, docetaxel (Taxotere) received FDA approval for metastatic androgen independent prostate cancer as the first chemotherapy to extend survival. Since then, numerous studies have investigated...
View ArticleClik here to view.
New tech may bring exciting era in BPH
Steven A. Kaplan, MDDr. Kaplan is E. Darracott Vaughan Jr. Professor of Urology at Weill Cornell Medical College and director of the Iris Cantor Men's Health Center, New York Presbyterian Hospital, New...
View ArticleClik here to view.
A curative therapy for ED edges forward
Arthur L. Burnett, II, MD, MBADr. Burnett, a member of the Urology Times Editorial Council, is professor of urology at Johns Hopkins University School of Medicine, Baltimore. He serves as an...
View ArticleClik here to view.
Robotics finding a role in prolapse repair
J. Stuart Wolf, Jr, MDWith the widespread acceptance of robot-assisted surgery for reconstructive procedures such as radical prostatectomy and partial nephrectomy, the next frontier for urologic...
View ArticleClik here to view.
IPP satisfaction: What you can anticipate
Allen F. Morey, MDDr. Morey, a member of the Urology Times Editorial Council, is professor of urology at the University of Texas Southwestern Medical Center, Dallas. Patient dissatisfaction rates of...
View Article
